Psychedelics biopharma company Reunion Neuroscience Inc. (NASDAQ: REUN) reported its business update and fiscal results for the second quarter ended September 30, 2022.

Reunion’s president and CEO Greg Mayes stated that the company has consolidated as an independent company and is “well positioned to round out the year in preparation for what promises to be an exciting 2023.” 

Mayes further announced that Reunion has dosed all subjects in the first four cohorts of its Phase 1 study for which a readout date has been set for some time within Q1 2023. The company is strengthening its leadership team with newly-appointed Edward Smith as CFO, Dr. Aviva Asnis-Alibozek VP of medical affairs and Curtis Weber general counsel to advance its next growth stage.

“Reunion’s strong composition of matter IP significantly differentiates us from other psychedelic therapeutic companies. Making Reunion even more exciting is the company’s development program, which targets a niche initial indication with high unmet therapeutic need –PPD [Post-Partum Depression],” the company’s CEO said.

Financial results: On September 30, 2022 Reunion …

Full story available on Benzinga.com